29 jun: Shipping/Sydbank: Lave rater presser over hele linjen
29 jun: Obligationer/middag: Jubeloptimismen dæmpet en smule
29-06-2012 11:40:00

UPDATE: AB InBev to Buy Remaining Grupo Modelo Stake for $20.1 Billion

Relateret indhold

--AB InBev to pay $9.15 per share in cash

--Move would give AB InBev full control of Corona Extra brand

--Antitrust regulators' approval remains question mark

(Rewrites throughout, adds analyst comment in seventh paragraph.)

BRUSSELS--Anheuser-Busch InBev NV (ABI.BT) said Friday it is acquiring the stake it doesn't yet own in Mexican brewer Grupo Modelo SAB (GMODELO.MX) in a deal worth $20.1 billion that would give the Belgian company full control of Corona Extra, one of the world's top beer brands, and cement its position in the growing South American market.

In a joint statement, the companies said the merger will be "completed through a series of steps that will simplify Grupo Modelo's corporate structure, followed by an all-cash tender offer by AB InBev for all outstanding Grupo Modelo shares."

They said the tender price for the shares -- AB InBev is offering $9.15 per share in cash -- represents a premium of around 30% to Grupo Modelo's closing price on June 22.

AB InBev already owns a non-controlling 50% stake in Grupo Modelo and the combined company would "lead the global beer industry" with estimated 2012 revenues of $47 billion from operations in 24 countries, the companies said.

The Modelo sale to AB InBev ends a contentious history between the companies. AB InBev won its 50% Modelo stake through InBev's $52 billion acquisition in 2008 of Budweiser producer Anheuser-Busch, a deal that created the world's largest beer maker by sales. Anheuser had tried unsuccessfully to entice Modelo to merge with the U.S. brewing giant after it received the unsolicited approach from InBev, people familiar with the matter said at the time.

Approval of the deal by antitrust regulators remains a question mark, as AB InBev has considerable market power in the U.S. and elsewhere. Modelo has some strong brands, especially Corona.

"The combination of both breweries creates a pan-American powerhouse with number one or two positions in every major market from Canada to Argentina," said Marc Leemans, an analyst at Bank Degroof in Brussels.

The move will increase competitive pressure in Mexico and create a stronger rival for Heineken NV (HEIA.AE) there, SNS Securities added. The broker said Grupo Modelo has a market share of around 56% in Mexico, while Heineken holds roughly 41% through its Femsa unit. Competition will likely heat up as soon as AB Inbev realizes synergies from its tie-up with Grupo Modelo, SNS said.

The two companies said they believed the cost savings from the merger would be worth at least $600 million annually.

"There is tremendous opportunity from combining two leading brand portfolios and further expanding Grupo Modelo's brands worldwide through AB InBev's extensive global distribution network," said Carlos Brito, Chief Executive of Anheuser-Busch InBev.

The companies said Grupo Modelo would keep its name and identity, would continue to be headquartered in Mexico City and would keep its local board.

--Amy Guthrie in Mexico City and Alessandro Torello in Brussels contributed to this article.

Write to Laurence Norman at Laurence.norman@dowjones.com

(END) Dow Jones Newswires

June 29, 2012 05:40 ET (09:40 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: Faldende USA-salg kan sætte fokus på Genmab

23-08-2017 08:23:37
På en onsdag med regnskaber fra flere selskaber uden for C20 Cap kan Genmab komme i fokus, efter at nye tal viser, at salget af kræftmidlet Darzalex faldt på det amerikanske marked i juli i forhold til juni.Generelt vil det dog være "en åbning omkring nul", efter at kursstigninger fra USA ikke har forplantet sig til Asien, fordi der i kulissen igen spøger politisk uro i USA, vurderer Morten Hessne..

Zealand Pharma kan se frem til milepælsbetaling på 4 mio. euro

22-08-2017 16:00:43
Zealand Pharma kan se frem til at modtage 4 mia. euro (30 mio. kr.) som en milepælsbetaling, efter at selskabets tyske partner, Boehringer Ingelheim, har annonceret igangsætningen af to fase-1-studier med et midler udviklet af det danske biotekselskab.De to studier skal vise mulighederne for anvendelsen af medikamenterne til behandling af fedme og/eller diabetes. Det gælder blandt andet lægemiddel..

Matas/Danske: Regnskab med lavere omsætning var forventet

22-08-2017 13:53:03
Matas' regnskab for første kvartal i det forskudte regnskabsår 2017/2018 var som forventet.Det vurderer Poul Ernst Jessen, senioranalytiker i Danske Bank.- Regnskabet er som forventet. Det eneste overraskende er ledelsesændringen, siger Poul Ernst Jessen.Materialistkædens omsætning faldt 3,2 pct. til 820,9 mio. kr., mens driftsresultatet (EBITA) var 119 mio. kr. Danske Bank forventede en omsætning..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Tirsdagens aktier: Pandora tog revanche og stor stigning i C20 Cap
2
Aktier/tendens: Faldende USA-salg kan sætte fokus på Genmab
3
Zealand Pharma kan se frem til milepælsbetaling på 4 mio. euro
4
Bavarian: Johnson & Johnson bliver storaktionær efter samarbejdsaftale
5
Mærsk: Johan Uggla bliver direktør for Maersk Training - citat

Relaterede aktiekurser

AB Inbev 98,63 -0,9% Fald i aktiekurs
Heineken 87,14 -0,1% Fald i aktiekurs
Anheuser-Busch Inbev SA .. 116,89 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. august 2017 12:02:33
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170821.2 - EUROWEB7 - 2017-08-23 12:02:33 - 2017-08-23 12:02:33 - 1 - Website: OKAY